Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020)
Forte Biosciences (FBRX) posted quarterly Non Operating Investment Income of -$10000.0 for Q1 2020, down 124.39% year-over-year from $41000.0 in Q2 2019, and up 69.7% quarter-over-quarter from -$33000.0 in Q4 2019.
Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Non Operating Investment Income for 5 consecutive years, with -$10000.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Non Operating Investment Income fell 124.39% year-over-year to -$10000.0; the TTM figure through Mar 2020 stood at -$18000.0 (down 114.29% YoY), while the FY2019 annual figure was $33000.0, up 200.0% from the prior year.
- Non Operating Investment Income grew to -$10000.0 in Q1 2020 per FBRX's latest filing, from -$33000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $54000.0 in Q1 2016 and bottomed at -$74000.0 in Q1 2018.
- Historically, Non Operating Investment Income has averaged $3866.7 across 5 years, with a median of -$1000.0 in 2017.
- On a YoY basis, Non Operating Investment Income climbed as much as 1000.0% in 2018 and fell as far as 7300.0% in 2018.
- Forte Biosciences' Non Operating Investment Income stood at -$9000.0 in 2016, then plunged by 244.44% to -$31000.0 in 2017, then surged by 200.0% to $31000.0 in 2018, then tumbled by 206.45% to -$33000.0 in 2019, then jumped by 69.7% to -$10000.0 in 2020.
- Business Quant data shows FBRX's Non Operating Investment Income at -$10000.0 in Q1 2020, -$33000.0 in Q4 2019, and -$13000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -10,000.00 |
| Mar 31, 2020 | -10,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Sep 30, 2019 | -13,000.00 |
| Sep 30, 2019 | -13,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Mar 31, 2019 | 41,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Mar 31, 2018 | -74,000.00 |
| Mar 31, 2018 | -74,000.00 |
| Dec 31, 2017 | -31,000.00 |
| Dec 31, 2017 | -31,000.00 |
| Sep 30, 2017 | 4,000.00 |
| Sep 30, 2017 | 4,000.00 |